February 16, 2021
11 am to 12 pm EST
Schedule conflict?
Register and you'll receive a copy of the recording!
 
Serious Synthetic Biology: Engineered Cynomologous mAbs for Improved Immunogenicity Studies

Webinar Description:

The immunogenicity of biotherapeutics presents a major challenge during the clinical development of new protein drugs including monoclonal antibodies. To address this, multiple humanization and de‐immunization techniques that employ in silico algorithms and in vitro test systems have been proposed and implemented.

In this webinar we will discuss antibody humanization and de‐immunization strategies to reduce the risk of anti‐drug antibody (ADA) development, highlighting an example of using cynomolgus macaque as a surrogate for human.

Learning Objectives:

Immunogenecity and antibody development. Designing monoclonal antibodies with cross-species synthetic biology to reduce risk in antibody development.

Speakers:

#

Lukasz Chlewicki
Eli Lilly Pharmaceuticals

Luke earned his Ph.D. in Cell and Structural Biology at the University of Illinois at Urbana-Champaign, where he engineered NK and T cell receptors for Class I MHC. Luke did his postdoctoral work studying NK receptor signaling for Vinay Kumar in the Pathology department at the University of Chicago. Luke then took a position as Assistant Professor for Yang-Xin Fu at the University of Chicago, where he worked on engineering immuno-cytokines to treat metastatic breast cancer. Luke then joined the Lead Optimization group at Boehringer Ingelheim in 2010. At BI, Luke engineered and de-immunized various biotherapeutic compounds. Luke joined the Investigative BioTDR ADME group at Eli Lilly in 2014, where he works on optimizing the ADME properties of different biologic modalities, as well as serving as a member of Lilly’s Immunogenicity risk strategy teams.

#

Sridhar Govindarajan

As ATUM’s Co-founder and CIO, Dr. Sridhar Govindarajan leads the company's automation and protein engineering efforts. He has more than 20 years of scientific computing experience. Prior to his current position, Govindarajan led the computational research in optimizing directed evolution technologies at Maxygen, Inc., and was a Systems Architect at EraGen Biosciences. Dr. Govindarajan was a Junior Research Fellow at the Indian Institute of Technology (IIT)'s Department of Chemistry and received his PhD in Computational Chemistry/Biophysics from the University of Michigan's Department of Chemistry.


Cost: No Cost!